Raymond James: 'PROF meeting its FY26 revenue guidance is very much achievable'
Tweet Send to a Friend
Raymond James analyst Michael Freeman reiterated a Strong Buy rating and $11.00 price target on Profound Medical Corp. (NASDAQ: PROF).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




